Background Cytomegalovirus (CMV) is a major cause of infection in the early period after heart transplantation (HTx). There are limited data comparing universal prophylaxis with preemptive treatment of CMV infection in HTx recipients. Therefore, the goal of this study was to evaluate efficacy and safety of both strategies. Methods A total of 17 HTx recipients were prospectively enrolled in the universal prophylaxis group. This study cohort was matched with 18 HTx recipients who had the same immunosuppressive regimen and received preemptive therapy for CMV infection. All patients were CMV-seropositive. The study group received oral valganciclovir in a dose of 900 mg daily for 100 days. The second group was treated in case of CMV viraemia higher than 500 copies/ml. The incidence of CMV infection, other opportunistic infections and acute graft rejection and adverse events were evaluated at 3th, 6th and 12th months post-transplant. Results Universal prophylaxis was tolerated in 87.5% of the patients for a period of 100 days. Leukopenia was the most frequent side-effect that appeared in 25% of this group. This strategy decreased the rate of asymptomatic CMV infection during the first 3 months after HTx (11.7% vs. 55.6%, p=0.006) compared with preemptive therapy. This positive effect was associated with lower incidence of acute graft rejection at 12 months of follow up (6.3% vs. 41.2%, p=0.015). Conclusion Universal prophylaxis, with valganciclovir in CMV-seropositive HTx recipients, was acceptably safe and compared with preemptive therapy of CMV infection reduced the incidence of asymptomatic CMV infection and of acute graft rejection.

Klinika kardiologie IKEM Praha

Obsahuje 3 tabulky

Literatura

000      

00000naa a2200000 a 4500

001      

bmc12008587

003      

CZ-PrNML

005      

20190820155121.0

007      

ta

008      

120316s2012 xr f 000 0eng||

009      

AR

024    7_

$2 doi $a 10.1016/j.crvasa.2012.01.009

040    __

$a ABA008 $d ABA008 $e AACR2 $b cze

041    0_

$a eng $b cze

044    __

$a xr

100    1_

$a Vymětalová, Yevheniya $7 xx0095495 $u Klinika kardiologie, IKEM, Praha

245    10

$a Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients / $c Jevgenije Vymětalová, Miloš Kubánek, Tomáš Gazdič, Jana Vrbská, Ivan Málek, Josef Kautzner

500    __

$a Obsahuje 3 tabulky

504    __

$a Literatura $b 21

520    9_

$a Background Cytomegalovirus (CMV) is a major cause of infection in the early period after heart transplantation (HTx). There are limited data comparing universal prophylaxis with preemptive treatment of CMV infection in HTx recipients. Therefore, the goal of this study was to evaluate efficacy and safety of both strategies. Methods A total of 17 HTx recipients were prospectively enrolled in the universal prophylaxis group. This study cohort was matched with 18 HTx recipients who had the same immunosuppressive regimen and received preemptive therapy for CMV infection. All patients were CMV-seropositive. The study group received oral valganciclovir in a dose of 900 mg daily for 100 days. The second group was treated in case of CMV viraemia higher than 500 copies/ml. The incidence of CMV infection, other opportunistic infections and acute graft rejection and adverse events were evaluated at 3th, 6th and 12th months post-transplant. Results Universal prophylaxis was tolerated in 87.5% of the patients for a period of 100 days. Leukopenia was the most frequent side-effect that appeared in 25% of this group. This strategy decreased the rate of asymptomatic CMV infection during the first 3 months after HTx (11.7% vs. 55.6%, p=0.006) compared with preemptive therapy. This positive effect was associated with lower incidence of acute graft rejection at 12 months of follow up (6.3% vs. 41.2%, p=0.015). Conclusion Universal prophylaxis, with valganciclovir in CMV-seropositive HTx recipients, was acceptably safe and compared with preemptive therapy of CMV infection reduced the incidence of asymptomatic CMV infection and of acute graft rejection.

650    _2

$a transplantace srdce $x imunologie $7 D016027

650    _2

$a rejekce štěpu $x etiologie $x virologie $7 D006084

650    _2

$a oportunní infekce $x epidemiologie $x virologie $7 D009894

650    _2

$a cytomegalovirové infekce $x epidemiologie $x krev $x prevence a kontrola $7 D003586

650    _2

$a chemoprofylaxe $x metody $7 D018890

650    _2

$a ganciklovir $x aplikace a dávkování $x farmakologie $x škodlivé účinky $7 D015774

650    _2

$a viremie $x epidemiologie $x farmakoterapie $7 D014766

650    _2

$a leukopenie $x epidemiologie $x chemicky indukované $7 D007970

650    _2

$a lidé $7 D006801

650    _2

$a prospektivní studie $7 D011446

650    _2

$a financování organizované $7 D005381

653    00

$a rejekce

700    1_

$a Kubánek, Miloš $7 xx0083616 $u Klinika kardiologie, IKEM, Praha

700    1_

$a Gazdič, Tomáš $7 xx0210911 $u Klinika kardiologie, IKEM, Praha

700    1_

$a Vrbská, Jana $7 xx0097372 $u Klinika kardiologie, IKEM, Praha

700    1_

$a Málek, Ivan, $d 1942- $7 nlk20030129885 $u Klinika kardiologie, IKEM, Praha

700    1_

$a Kautzner, Josef, $d 1957- $7 xx0037112 $u Klinika kardiologie, IKEM, Praha

773    0_

$t Cor et vasa $x 0010-8650 $g Roč. 54, č. 1-2 [1] (2012), s. 26-32 (e e16-e21) $w MED00010972

856    41

$u https://e-coretvasa.cz/pdfs/cor/2012/01/11.pdf $y plný text volně přístupný

910    __

$a ABA008 $b A 2980 $c 438 $y 2 $z 0

990    __

$a 20120316081655 $b ABA008

991    __

$a 20190820155357 $b ABA008

999    __

$a ok $b bmc $g 901683 $s 765482

BAS    __

$a 3

BMC    __

$a 2012 $b 54 $c 1-2 $g 1 $d 26-32 $f e16-e21 $i 0010-8650 $m Cor et Vasa (Brno) $n Cor Vasa (Brno Print) $x MED00010972

GRA    __

$a NT11262 $p MZ0

LZP    __

$a 2012-12/vtmv